Tumor DNA hunt during pancreatic surgery may predict outcomes
NCT ID NCT06478056
First seen Feb 06, 2026 · Last updated May 25, 2026 · Updated 17 times
Summary
This study looked at 40 adults with operable pancreatic cancer to measure circulating tumor DNA (ctDNA) in blood from a vein and from the portal vein during surgery, as well as in fluid from the abdomen. The goal was to see if these DNA levels could help predict how the disease progresses. The study did not test a new treatment, but rather gathered information to better understand the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Hospital, Rouen
Rouen, 76031, France
Conditions
Explore the condition pages connected to this study.